CN115151568A - 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法 - Google Patents

用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法 Download PDF

Info

Publication number
CN115151568A
CN115151568A CN202080096917.XA CN202080096917A CN115151568A CN 115151568 A CN115151568 A CN 115151568A CN 202080096917 A CN202080096917 A CN 202080096917A CN 115151568 A CN115151568 A CN 115151568A
Authority
CN
China
Prior art keywords
antibody
antigen
seq
subject
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096917.XA
Other languages
English (en)
Chinese (zh)
Inventor
H·古劳克
E－B·哈达德
S·哈蒙
S·哈雷尔
G·卡利奥利亚斯
M·拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN115151568A publication Critical patent/CN115151568A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080096917.XA 2019-12-23 2020-12-22 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法 Pending CN115151568A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962952996P 2019-12-23 2019-12-23
US62/952,996 2019-12-23
US202062964970P 2020-01-23 2020-01-23
US62/964,970 2020-01-23
PCT/US2020/066559 WO2021133776A1 (en) 2019-12-23 2020-12-22 Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist

Publications (1)

Publication Number Publication Date
CN115151568A true CN115151568A (zh) 2022-10-04

Family

ID=74191948

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096917.XA Pending CN115151568A (zh) 2019-12-23 2020-12-22 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法

Country Status (11)

Country Link
US (1) US20230340101A1 (enExample)
EP (1) EP4081544A1 (enExample)
JP (2) JP2023508360A (enExample)
KR (1) KR20220119446A (enExample)
CN (1) CN115151568A (enExample)
AU (1) AU2020415382A1 (enExample)
BR (1) BR112022011388A2 (enExample)
CA (1) CA3162507A1 (enExample)
IL (1) IL294066A (enExample)
MX (1) MX2022007958A (enExample)
WO (1) WO2021133776A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117949666A (zh) * 2024-01-12 2024-04-30 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CA3236201A1 (en) * 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
KR20250017964A (ko) * 2023-07-28 2025-02-04 재단법인 아산사회복지재단 혈액 단백체를 이용한 생물학적 제제에 대한 천식 치료 반응성 예측을 위한 바이오마커 및 이의 용도
WO2025088063A2 (en) * 2023-10-24 2025-05-01 Sanofi Systems and methods for monitoring a medicament dosing schedule

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
NZ609557A (en) 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
JO3532B1 (ar) * 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AR108263A1 (es) * 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
HUE067888T2 (hu) * 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
BR112022000740A2 (pt) * 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117949666A (zh) * 2024-01-12 2024-04-30 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用
WO2025087446A1 (zh) * 2024-01-12 2025-05-01 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用
CN117949666B (zh) * 2024-01-12 2025-07-15 首都医科大学附属北京同仁医院 一种预测或评估抗IL-4Rα单抗在治疗鼻黏膜2型炎症相关鼻病疗效的标志物、方法和应用

Also Published As

Publication number Publication date
MX2022007958A (es) 2022-10-07
JP2026068738A (ja) 2026-04-22
BR112022011388A2 (pt) 2022-08-30
AU2020415382A1 (en) 2022-08-18
CA3162507A1 (en) 2021-07-01
EP4081544A1 (en) 2022-11-02
JP2023508360A (ja) 2023-03-02
KR20220119446A (ko) 2022-08-29
IL294066A (en) 2022-08-01
US20230340101A1 (en) 2023-10-26
WO2021133776A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
JP6306588B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN115151568A (zh) 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法
JP2021501169A (ja) Ｉｌ−４ｒ拮抗薬の投与により喘息を処置または予防するための方法
EP3973987A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2020266593B2 (en) Methods for treating or preventing asthma by administering an IL-33 antagonist
JP2019531273A (ja) Ｉｌ−４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
US20220169739A1 (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CN115175700B (zh) 用于通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP2025164767A (ja) Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法
EA050548B1 (ru) Способы лечения или предупреждения аллергической астмы посредством введения антагониста il-33 и/или антагониста il-4r
RU2838119C2 (ru) Способы лечения или предупреждения астмы посредством введения антагониста il-33
JP6923594B2 (ja) Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN116848138A (zh) 通过施用il-4r拮抗剂治疗儿科受试者的哮喘的方法
IL301777A (en) Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
EA052377B1 (ru) Применение антитела, которое специфически связывает il-33, для лечения copd

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: France

Address after: French Gentilly

Applicant after: SANOFI BIOTECHNOLOGY

Country or region after: U.S.A.

Applicant after: REGENERON PHARMACEUTICALS, Inc.

Address before: Paris France

Applicant before: SANOFI BIOTECHNOLOGY

Country or region before: France

Applicant before: REGENERON PHARMACEUTICALS, Inc.

Country or region before: U.S.A.

CB02 Change of applicant information